Can Fite Biofarma(CANF),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community - To The Moon

At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.

Close

CANF Can Fite Biofarma

Market Closed 12-12 16:00:00 EST

0.2828

-0.0063

-2.18%

盘后0.2830

+0.0002+0.07%

19:58 EST

High0.2988	Low0.2820	Vol629.36K
Open0.2915	D1 Closing0.2891	Amplitude5.81%
Mkt Cap4.83M	Tradable Cap4.83M	Total Shares17.07M
T/O182.23K	T/O Rate3.69%	Tradable Shares17.07M
P/B--	ROE--	EPS0.00
52wk High--	52wk Low--	P/E--
Dividend--	Div.Yield--	ROA--

Loading ...

{"stockData":{"symbol":"CANF","market":"US","secType":"STK","nameCN":"Can Fite Biofarma","latestPrice":0.2828,"timestamp":1765573200000,"preClose":0.2891,"halted":0,"volume":629359,"hourTrading":{"tag":"盘后","latestPrice":0.283,"preClose":0.2828,"latestTime":"19:58 EST","volume":20236,"amount":5696.0633,"timestamp":1765587508353},"delay":0,"floatShares":17070600,"shares":17072900,"eps":-0.8883,"marketStatus":"Market Closed","change":-0.0063,"latestTime":"12-12 16:00:00 EST","open":0.2915,"high":0.2988,"low":0.282,"amount":182234.8004758,"amplitude":0.058111,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":-0.8883,"tradingStatus":0,"nextMarketStatus":{"tag":"Pre-Mkt","tradingStatus":1,"beginTime":1765789200000},"marketStatusCode":7,"adr":0,"adrRate":300,"listingDate":1384837200000,"exchange":"AMEX","adjPreClose":0.2891,"preHourTrading":{"tag":"盘前","latestPrice":0.2891,"preClose":0.2891,"latestTime":"09:24 EST","volume":9539,"amount":2732.6249293,"timestamp":1765549441939},"postHourTrading":{"tag":"盘后","latestPrice":0.283,"preClose":0.2828,"latestTime":"19:58 EST","volume":20236,"amount":5696.0633,"timestamp":1765587508353},"volumeRatio":0.9228860877062466},"requestUrl":"/m/hq/s/CANF","defaultTab":"news","newsList":[{"id":"2584968160","title":"Can-Fite Biopharma Is Maintained at Buy by D. Boral Capital","url":"https://stock-news.laohu8.com/highlight/detail?id=2584968160","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2584968160?lang=en_us&edition=fundamental","pubTime":"2025-11-19 03:40","pubTimestamp":1763494800,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/CANF/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  November 18, 2025 14:40 ET (19:40 GMT)","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","CANF"],"gpt_icon":0},{"id":"2580738027","title":"Can-Fite Biopharma Coverage Assumed by HC Wainwright & Co. at Buy","url":"https://stock-news.laohu8.com/highlight/detail?id=2580738027","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2580738027?lang=en_us&edition=fundamental","pubTime":"2025-11-04 19:50","pubTimestamp":1762257000,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/CANF/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  November 04, 2025 06:50 ET (11:50 GMT)","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["CANF","BK4139"],"gpt_icon":0},{"id":"2578621851","title":"Can-Fite BioPharma’s Promising Phase 2 Study on Namodenoson for Pancreatic Cancer","url":"https://stock-news.laohu8.com/highlight/detail?id=2578621851","media":"TIPRANKS","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2578621851?lang=en_us&edition=fundamental","pubTime":"2025-10-28 01:13","pubTimestamp":1761585200,"startTime":"0","endTime":"0","summary":"Can-Fite BioPharma Ltd (($CANF)) announced an update on their ongoing clinical study. Can-Fite BioPharma Ltd (CANF) is conducting a Phase 2 clinica...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/can-fite-biopharmas-promising-phase-2-study-on-namodenoson-for-pancreatic-cancer?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/can-fite-biopharmas-promising-phase-2-study-on-namodenoson-for-pancreatic-cancer?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["CANF","BK4139"],"gpt_icon":0},{"id":"2567101275","title":"Can-Fite Biopharma Is Maintained at Buy by D. Boral Capital","url":"https://stock-news.laohu8.com/highlight/detail?id=2567101275","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2567101275?lang=en_us&edition=fundamental","pubTime":"2025-09-16 19:14","pubTimestamp":1758021240,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/CANF/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  September 16, 2025 07:14 ET (11:14 GMT)","market":"other","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","CANF"],"gpt_icon":0},{"id":"2564801170","title":"Can-Fite Biopharma Is Maintained at Buy by D. Boral Capital","url":"https://stock-news.laohu8.com/highlight/detail?id=2564801170","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2564801170?lang=en_us&edition=fundamental","pubTime":"2025-09-02 19:36","pubTimestamp":1756812960,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/CANF/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  September 02, 2025 07:36 ET (11:36 GMT)","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["CANF"],"gpt_icon":0},{"id":"2562037510","title":"Press Release: Can-Fite Reports H1 2025 Financial Results and Clinical Update","url":"https://stock-news.laohu8.com/highlight/detail?id=2562037510","media":"Dow Jones","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2562037510?lang=en_us&edition=fundamental","pubTime":"2025-08-28 20:47","pubTimestamp":1756385220,"startTime":"0","endTime":"0","summary":"Ramat Gan, Israel, Aug. 28, 2025  -- Can-Fite BioPharma Ltd.  , a biotechnology company developing a pipeline of proprietary small molecule drugs targeting oncological and inflammatory diseases, today announced financial results and clinical updates for H1, 2025.Pancreatic Cancer Phase 2a Study with Can-Fite's Namodenoson Achieved Over 50% Enrollment Milestone. The Phase 2a study  is a multicenter, open-label trial enrolling patients with advanced pancreatic adenocarcinoma whose disease has progressed following at least one line of prior therapy. The study is evaluating the safety , clinical activity, and pharmacokinetics  of Namodenoson in this patient population. Participants receive oral Namodenoson at a dose of 25 mg, administered twice daily in continuous 28-day cycles. Patients are regularly monitored for safety, and to date, Namodenoson has demonstrated a favorable safety profile. The study is led by Prof. Salomon Stemmer, a renowned oncologist and key opinion leader at the Davi","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","BK4218","PK","CANF","BK4181"],"gpt_icon":0},{"id":"2555705818","title":"Can-Fite BioPharma Prices $15 Million Public Offering of Securities","url":"https://stock-news.laohu8.com/highlight/detail?id=2555705818","media":"MT Newswires Live","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2555705818?lang=en_us&edition=fundamental","pubTime":"2025-07-29 01:20","pubTimestamp":1753723250,"startTime":"0","endTime":"0","summary":"Can-Fite BioPharma  priced a public offering to a single institutional investor of 8.33 million American depositary shares and accompanying warrants to purchase up to 16.67 million ADS at a combined price of $0.60 apiece for total proceeds of up to $15 million.The warrants are exercisable immediately upon issuance at $0.60 per ADS, expiring after two years, the company said Monday in a statement.Can-Fite expects to close the offering around Tuesday and said proceeds will be used for funding research, clinical trials and general corporate purposesPrice: 0.70, Change: -0.28, Percent Change: -28.57","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK4139","CANF"],"gpt_icon":0},{"id":"2555080197","title":"Amex Halt  News Pending Lst 0.838300","url":"https://stock-news.laohu8.com/highlight/detail?id=2555080197","media":"THOMSON REUTERS","labels":["event"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2555080197?lang=en_us&edition=fundamental","pubTime":"2025-07-29 00:10","pubTimestamp":1753719009,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250728:nAQN2KOG0W:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"event","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["CANF","BK4139"],"gpt_icon":0}],"profile":{"websiteUrl":"http://www.canfite.com","stockEarnings":[{"period":"1week","weight":-0.0965},{"period":"1month","weight":-0.2696},{"period":"3month","weight":-0.5713},{"period":"6month","weight":-0.7357},{"period":"1year","weight":-0.8265},{"period":"ytd","weight":-0.826}],"compareEarnings":[{"period":"1week","weight":-0.0057},{"period":"1month","weight":-0.0024},{"period":"3month","weight":0.037},{"period":"6month","weight":0.142},{"period":"1year","weight":0.1281},{"period":"ytd","weight":0.1633}],"compareStock":{"symbol":"SPY","name":"SPDR S&P 500 ETF Trust"},"description":"Can-Fite BioPharma Ltd., a clinical-stage biopharmaceutical company, develops orally bioavailable small molecule therapeutic products for the treatment of cancer, liver inflammatory diseases, and erectile dysfunction in Israel. The company's lead drug candidate Piclidenoson, which has been completed Phase III clinical trial for the treatment of psoriasis. It develops Namodenoson that is in Phase III clinical trial for the treatment of liver cancer; and Phase IIa for the treatment of pancreatic cancer; as well as in Phase IIb trial for the treatment of metabolic associated steatohepatitis; and CF602, which is in pre-clinical trial for the treatment of erectile dysfunction. In addition, the company develops commercial predictive biomarker blood test kit for A3AR. It has license and collaboration agreement with CMS Medical to develop, manufacture, and commercialize Piclidenoson and Namodenoson; and collaboration agreement with Univo Pharmaceuticals to identify and co-develop specific formulations of cannabis components for the treatment of cancer, inflammatory, autoimmune, and metabolic diseases. The company was formerly known as Can-Fite Technologies Ltd. and changed its name to Can-Fite BioPharma Ltd. in January 2001. The company was incorporated in 1994 and is headquartered in Ramat Gan, Israel.","yearOnYearQuotes":[{"month":1,"riseRate":0.166667,"avgChangeRate":-0.08289},{"month":2,"riseRate":0.583333,"avgChangeRate":-0.00614},{"month":3,"riseRate":0.416667,"avgChangeRate":-0.067966},{"month":4,"riseRate":0.25,"avgChangeRate":-0.06706},{"month":5,"riseRate":0.416667,"avgChangeRate":-0.022087},{"month":6,"riseRate":0.333333,"avgChangeRate":-0.014382},{"month":7,"riseRate":0.25,"avgChangeRate":-0.033089},{"month":8,"riseRate":0.333333,"avgChangeRate":-0.032507},{"month":9,"riseRate":0.333333,"avgChangeRate":0.032332},{"month":10,"riseRate":0.25,"avgChangeRate":-0.068864},{"month":11,"riseRate":0.583333,"avgChangeRate":0.063516},{"month":12,"riseRate":0.230769,"avgChangeRate":-0.086484}],"exchange":"AMEX","name":"Can Fite Biofarma","nameEN":"Can Fite Biofarma"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.35.11","shortVersion":"4.35.11","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Can Fite Biofarma(CANF),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest Can Fite Biofarma(CANF) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"Can Fite Biofarma,CANF,Can Fite Biofarma股票,Can Fite Biofarma股票老虎,Can Fite Biofarma股票老虎国际,Can Fite Biofarma行情,Can Fite Biofarma股票行情,Can Fite Biofarma股价,Can Fite Biofarma股市,Can Fite Biofarma股票价格,Can Fite Biofarma股票交易,Can Fite Biofarma股票购买,Can Fite Biofarma股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Can Fite Biofarma(CANF),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest Can Fite Biofarma(CANF) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}